• In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense, an FDA-approved, RNA-based at-home colorectal cancer screening test now covered for eligible Medicare beneficiaries.
• Together, these tools suggest Labcorp is deepening its role in simplifying early detection of liver and colorectal disease through less invasive, broadly accessible diagnostics.
• We’ll now examine how the expansion of Labcorp’s advanced blood and RNA-based tests may influence its longer-term investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Labcorp Holdings Investment Narrative Recap

To own Labcorp, you need to believe in its role as a scaled, innovation-focused diagnostics provider that can keep adding clinically relevant tests while managing cost and reimbursement pressures. The latest launches in liver and colorectal screening support that story, but do not materially change the near term focus on execution against 2026 revenue guidance and on managing pricing and reimbursement risks, including potential pressures from PAMA and competitive bidding.

Among the recent announcements, the nationwide rollout and Medicare coverage of ColoSense stands out as most relevant here, because it shows how Labcorp can extend its footprint in cancer screening using newer modalities like RNA-based stool tests. That kind of expansion in oncology and preventive testing sits directly alongside MASLD and MASH blood tools as part of the same catalyst: growing test breadth to capture more volume while trying to offset reimbursement headwinds.

Yet while this growth in advanced testing is encouraging, investors should also be aware of how potential reimbursement changes could...

Labcorp Holdings’ narrative projects $16.3 billion revenue and $1.3 billion earnings by 2029.

Uncover how Labcorp Holdings' forecasts yield a $310.12 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates for Labcorp span about US$260 to US$518 per share, showing very different expectations for upside. Against that backdrop, ongoing concerns about PAMA and broader pricing pressure could shape how those varied views translate into future revenue and earnings resilience.

Explore 3 other fair value estimates on Labcorp Holdings - why the stock might be worth as much as 81% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Labcorp Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.